Patent Claims

- 1. Nutrition trace element composition, characterised in that one daily dose of the composition contains 0.04 2 mg of selenium and / or 10 mg 100 mg of zinc as trace element(s).
- 2. Composition according to Claim 1, characterised in that iron is not contained as a trace element.
- 3. Composition according to one of the Claims 1 2, characterised in that the composition exists as an infusion solution.
- 4. Composition according to Claim 3, characterised in that the infusion solution exists in a form suitable for parenteral administration.
- 5. Composition according to one of the Claims 1 4, characterised in that it exists as a concentrate with 0.004 mg 0.2 mg/ml of selenium and / or 1 mg 10 mg/ml of zinc.
- 6. Composition according to one of the Claims 1 5, characterised in that it exists as an aqueous solution for injection purposes.
- 7. Composition according to one of the Claims 1 6, characterised in that further trace elements are present, which are selected from chromium, copper, fluorine, iodine, manganese and molybdenum.
- 8. Composition according to one of the Claims 1 7, characterised in that the composition is formulated as a 10-ml infusion solution.
- 9. Administration unit of a composition according to one of the Claims 1 8, characterised in that it exists as an aqueous solution in an ampoule.
- 10. Use of selenium and / or zinc for nutrition, preferably for intensive care patients, particularly for sepsis patients, characterised in that the daily dose of selenium is

in the range from 0.04 mg - 2 mg and the daily dose of zinc is in the range from 10 mg - 100 mg.

- 11. Use according to Claim 10, characterised in that the daily dose of selenium amounts to at least 0.5 mg and the daily dose of zinc amounts to at least 10 mg.
- 12. Use according to Claim 11, characterised in that the trace elements are administered parenterally.
- 13. Use according to one of the Claims 10 12, characterised in that further trace elements, selected from chromium, copper, fluorine, iodine, manganese and molybdenum, are administered.
- 14. Use according to one of the Claims 11 13, characterised in that use of the trace element iron is refrained from in the administration.
- 15. Use according to one of the Claims 11 14, characterised in that the trace elements are administered for a period of at least 3 days, preferably at least 5 days.